on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Updates on U.S. Patent Filings for Drug Delivery Platform
Aspire Biopharma Holdings, Inc., listed on NASDAQ as ASBP, has announced an update on its patent applications for a sublingual drug delivery platform. The company originally filed provisional patents with the U.S. Patent and Trademark Office in March 2023 and October 2024. These patents cover formulations for rapidly absorbing aspirin via the oral mucosa, bypassing the gastrointestinal tract.
The patent filings are a strategic move to enhance Aspire's intellectual property portfolio. Aspire's CEO, Kraig Higginson, highlighted the potential of this technology to revolutionize sublingual drug delivery and improve treatment outcomes. Key benefits include fast absorption, vital for handling cardiac emergencies and pain management.
Aspire plans to initiate a bioavailability study in April 2025, with further clinical trials anticipated throughout the year. The company aims to bolster its path to commercialization with these developments.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news